Corvus Pharmaceuticals Q3 2021 Earnings Report
Key Takeaways
Corvus Pharmaceuticals reported a net loss of $10.7 million for the third quarter ended September 30, 2021, compared to a net loss of $9.8 million for the same period in 2020. As of September 30, 2021, the company had cash, cash equivalents, and marketable securities totaling $76.3 million.
Advanced clinical programs for mupadolimab, CPI-818, and ciforadenant.
Mupadolimab is being studied for NSCLC and head and neck cancer.
Angel Pharmaceuticals received IND approval in China for CPI-818 to treat T cell lymphomas.
Cash, cash equivalents, and marketable securities totaled $76.3 million as of September 30, 2021.
Corvus Pharmaceuticals
Corvus Pharmaceuticals
Forward Guidance
Corvus expects full year 2021 net cash used in operating activities to be approximately $36 million, resulting in a projected balance of cash, cash equivalents and marketable securities of approximately $70 million at December 31, 2021.